The results of post-hoc subgroup analysis of randomized clinical trials indicated that alirocumab and evolocumab significantly reduced circulating LDL-C and Lp(a), and increased HDL-C, without affecting glycemic levels in patients with T2DM (78, 79). Here, LPA is linked to type 2 diabetes mellitus.